Olympus Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 9.90 M
as on 23-10-2024
- Paid Up Capital ₹ 7.39 M
as on 23-10-2024
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 Cr
as on 23-10-2024
- Revenue 12.17%
(FY 2023)
- Profit 10.89%
(FY 2023)
- Ebitda -21.81%
(FY 2023)
- Net Worth 12.29%
(FY 2023)
- Total Assets 25.95%
(FY 2023)
About Olympus Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.90 M and a paid-up capital of Rs 7.39 M.
The company currently has active open charges totaling ₹2.00 Cr.
Latha Subramanian and Karnnanidhi Ramanar serve as directors at the Company.
- CIN/LLPIN
U24290TN2015PTC101114
- Company No.
101114
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jun 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Olympus Therapeutics Private Limited offer?
Olympus Therapeutics Private Limited offers a wide range of products and services, including Health Conditions, Pain Relief, Sexual Wellness, Sexual Health Supplements, Menopause, Heart Care.
Who are the key members and board of directors at Olympus Therapeutics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Latha Subramanian  | Managing Director | 20-Jan-2023 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Karnnanidhi Ramanar | Director | 24-Jun-2015 | Current |
Financial Performance of Olympus Therapeutics.
Olympus Therapeutics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12.17% increase. The company also saw a substantial improvement in profitability, with a 10.89% increase in profit. The company's net worth Soared by an impressive increase of 12.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Olympus Therapeutics?
In 2023, Olympus Therapeutics had a promoter holding of 64.39% and a public holding of 35.61%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Grandix Global Pharma Private LimitedActive 7 years 7 monthsLatha Subramanian and Karnnanidhi Ramanar are mutual person
Grandix Speciality Formulations Private LimitedActive 7 years 1 monthLatha Subramanian is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 02 Feb 2024 | ₹1.00 Cr | Open |
Hdfc Bank Limited Creation Date: 14 Jun 2023 | ₹1.00 Cr | Open |
How Many Employees Work at Olympus Therapeutics?
Olympus Therapeutics has a workforce of 128 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Olympus Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Olympus Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
